Company: RGBP
Filing Date: 2025-02-24
Form Type: 253G1
Source: 0001493152-25-008067
Chunk: 25

Company: Regen BioPharma Inc
Filing Date: 2025-02-24
Form: 253G1
Chunk 25
---
 1, 2022 to December 31, 2022 |     | HIGH |       |     | LOW |      |
|:-------------------------------------|:----|:-----|------:|:----|:----|-----:|
| First Quarter                        |     | $    | 10.89 |     | $   | 5.89 |

| January 1, 2023 to March 31, 2023 |     | HIGH |      |     | LOW |      |
|:----------------------------------|:----|:-----|-----:|:----|:----|-----:|
| Second Quarter                    |     | $    | 7.16 |     | $   | 1.25 |

| April 1, 2023 to June 30, 2023 |     | HIGH |      |     | LOW |      |
|:-------------------------------|:----|:-----|-----:|:----|:----|-----:|
| Third Quarter                  |     | $    | 2.28 |     | $   | 1.50 |

| 21 |

| July 1, 2023 to September 30, 2023 |     | HIGH |      |     | LOW |      |
|:-----------------------------------|:----|:-----|-----:|:----|:----|-----:|
| Fourth Quarter                     |     | $    | 2.00 |     | $   | 1.46 |

As of November 5, 2024 there were approximately 482 holders of our Common Stock.

As of November 5, 2024 there were approximately
479 holders of our Series A Preferred Stock.

As of November 5, 2024 there was 1 holder
of our Series AA Preferred Stock.

As of November 5, 2024 there were approximately
7 holders of our Series M Preferred Stock

As of November 5, 2024 there was one holder
of our Series NC Preferred Stock.

Dividends

No cash dividends were paid during the fiscal year ending September 30, 2024. We do not expect to declare cash dividends in the immediate future.

Director Independence

Audit Committee and Audit Committee Financial Expert

The members of the Company’s board of Directors may not be considered independent. The Company is not a “listed company” under Securities and Exchange Commission (“SEC”) rules and is therefore not required to have an audit committee comprised of independent directors. The